ArticleCancers2024

The Engineered Drug 3'UTRMYC1-18 Degrades the c-MYC-STAT5A/B-PD-L1 Complex In Vivo to Inhibit Metastatic Triple-Negative Breast Cancer.

Chidiebere U Awah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.